Arcus Biosciences (RCUS) Current Deferred Revenue (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Current Deferred Revenue of $79.0 million for Q1 2026, up 9.72% year-over-year from $72.0 million in Q1 2025, and up 1.28% quarter-over-quarter from $78.0 million in Q4 2025.
Arcus Biosciences (RCUS) Current Deferred Revenue (2017 - 2026) Analysis & Trends
Arcus Biosciences' Current Deferred Revenue history runs 10 years deep, the most recent figure standing at $79.0 million for Q1 2026.
- In Q1 2026, Current Deferred Revenue rose 9.72% year-over-year to $79.0 million; the TTM figure through Mar 2026 stood at $79.0 million (up 9.72% YoY), while the FY2025 annual figure was $78.0 million, down 75.55% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $79.0 million, up from $78.0 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $429.0 million in Q3 2023, with the low at $35.0 million in Q2 2023.
- The 5-year median for Current Deferred Revenue is $97.0 million (2022), against an average of $168.6 million.
- The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue jumped 834.29% in 2024, then sank 80.33% in 2025.
- Arcus Biosciences' Current Deferred Revenue stood at $97.0 million in 2022, then tumbled by 63.92% to $35.0 million in 2023, then soared by 811.43% to $319.0 million in 2024, then plunged by 75.55% to $78.0 million in 2025, then rose by 1.28% to $79.0 million in 2026.
- Business Quant data shows RCUS's Current Deferred Revenue at $79.0 million in Q1 2026, $78.0 million in Q4 2025, and $105.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.00 Mn |
| Mar 31, 2026 | 79.00 Mn |
| Dec 31, 2025 | 78.00 Mn |
| Sep 30, 2025 | 105.00 Mn |
| Jun 30, 2025 | 71.00 Mn |
| Mar 31, 2025 | 72.00 Mn |
| Dec 31, 2024 | 319.00 Mn |
| Sep 30, 2024 | 394.00 Mn |
| Jun 30, 2024 | 327.00 Mn |
| Mar 31, 2024 | 366.00 Mn |
| Dec 31, 2023 | 35.00 Mn |
| Sep 30, 2023 | 429.00 Mn |
| Jun 30, 2023 | 35.00 Mn |
| Mar 31, 2023 | 97.00 Mn |
| Dec 31, 2022 | 97.00 Mn |
| Sep 30, 2022 | 103.29 Mn |
| Jun 30, 2022 | 90.12 Mn |
| Dec 31, 2021 | 102.00 Mn |
| Sep 30, 2021 | 74.34 Mn |
| Jun 30, 2021 | 74.57 Mn |